For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 13,562 | 12,092* | 9,591 | 10,770 |
| General and administrative | 6,067 | 5,439* | 5,169 | 5,816 |
| Total operating expenses | 19,629 | 17,530 | 14,760 | 16,586 |
| Income (loss) from operations | -19,629 | -17,530* | -14,760 | -16,586 |
| Interest and investment income (expense) | 1,847 | 1,688* | 1,502 | 1,626 |
| Other income (expense) | - | 730* | - | 0 |
| Other income (expense), net | 1,847 | 2,418* | 1,502 | 1,626 |
| Net income (loss) | -17,782 | -15,112* | -13,258 | -14,960 |
| Net unrealized gain (loss) on marketable debt securities | -454 | 7 | 66 | -12 |
| Other comprehensive income (loss) | -454 | 7* | 66 | -12 |
| Comprehensive income (loss) | -18,236 | -15,105 | -13,192 | -14,972 |
| Basic EPS | -0.31 | -0.344 | -0.31 | -0.35 |
| Diluted EPS | -0.31 | -0.344 | -0.31 | -0.35 |
| Basic Average Shares | 57,538,833 | 43,965,428 | 42,272,104 | 42,270,855 |
| Diluted Average Shares | 57,538,833 | 43,965,428 | 42,272,104 | 42,270,855 |
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)